Cargando…

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands

Oncoprotein CIP2A a Cancerous Inhibitor of PP2A forms an “oncogenic nexus” by virtue of its control on PP2A and MYC stabilization in cancer cells. The expression and prognostic function of CIP2A in different solid tumors including colorectal carcinoma, head & neck cancers, gastric cancers, lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	De, Pradip, Carlson, Jennifer, Leyland-Jones, Brian, Dey, Nandini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148086/ https://www.ncbi.nlm.nih.gov/pubmed/25015035

Ejemplares similares

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells
por: De, Pradip, et al.
Publicado: (2018)

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers
por: De, Pradip, et al.
Publicado: (2016)

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers
por: De, Pradip, et al.
Publicado: (2016)

CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation
por: Puustinen, Pietri, et al.
Publicado: (2014)

Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells
por: Khan, Mohd Moin, et al.
Publicado: (2020)

Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer
por: Birkman, Eva‐Maria, et al.
Publicado: (2018)

Papillomavirus E5: the smallest oncoprotein with many functions
por: Venuti, Aldo, et al.
Publicado: (2011)

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): Could It Be a Promising Biomarker and Therapeutic Target in Parkinson’s Disease?
por: Yin, Sijia, et al.
Publicado: (2022)

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
por: Chen, Beibei, et al.
Publicado: (2023)

Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
por: Pavic, Karolina, et al.
Publicado: (2023)

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A
por: Yu, H-C, et al.
Publicado: (2014)

ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells
por: Khanna, Anchit, et al.
Publicado: (2011)

Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner
por: Dey, Nandini, et al.
Publicado: (2013)

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
por: LaRochelle, Jonathan R., et al.
Publicado: (2018)

The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers
por: Fujiki, Hirota, et al.
Publicado: (2018)

miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion
por: Zhang, Shihua, et al.
Publicado: (2020)

CIP2A facilitates the G1/S cell cycle transition via B‐Myb in human papillomavirus 16 oncoprotein E6‐expressing cells
por: Tian, Yonghao, et al.
Publicado: (2018)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
por: Zeng, Li-Fan, et al.
Publicado: (2014)

Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1
por: Zhang, Weifang, et al.
Publicado: (2015)

Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
por: Raveendra-Panickar, Dhanya, et al.
Publicado: (2021)

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy
por: Chen, Kuen-Feng, et al.
Publicado: (2015)

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
por: Saafan, Hisham, et al.
Publicado: (2021)

Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
por: Gehring, Kalle, et al.
Publicado: (2020)

Fusogenic-Oligoarginine Peptide-Mediated Delivery of siRNAs Targeting the CIP2A Oncogene into Oral Cancer Cells
por: Cantini, Liliana, et al.
Publicado: (2013)

CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance
por: Ventelä, Sami, et al.
Publicado: (2014)

RAC1 Takes the Lead in Solid Tumors
por: De, Pradip, et al.
Publicado: (2019)

Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects
por: Hartman, Zachary, et al.
Publicado: (2020)

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins
por: Li, Juan, et al.
Publicado: (2020)

The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase
por: Wei, Yong, et al.
Publicado: (2022)

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2017)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

CIP2A expression is increased in prostate cancer
por: Vaarala, Markku H, et al.
Publicado: (2010)

Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs
por: Willis, Scooter, et al.
Publicado: (2015)

Down’s Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship
por: Dey, Nandini, et al.
Publicado: (2017)

Many hands make light ions
Publicado: (1976)

The Seesaw with Many Right-Handed Neutrinos
por: Ellis, Jonathan Richard, et al.
Publicado: (2007)

Negative regulation of the SH2-homology-containing protein-tyrosine phosphatase-1 (Shp-1) P2 promoter by the HTLV-1 tax oncoprotein
por: Cheng, Jihua, et al.
Publicado: (2006)

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein
por: Nabarro, Stephen, et al.
Publicado: (2005)

MAP kinase phosphatase-1 - a new player at the nexus between sarcopenia and metabolic disease
por: Flach, Rachel J. Roth, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oj4qj3h8cue03og9etvu4ehvck